Darnitsa Pharmaceutical Company, Kiev, Ukraine
Active ingredients Vikasola-Darnitsa:
Who is shown Vicasol-Darnitsa?
Vitamin K hypovitaminosis in obstructivejaundice, malabsorption syndrome, celiac disease, small intestine, pancreas, small bowel resection, prolonged diarrhea, dysentery, Crohn's disease, sprue, ulcerative colitis, parenteral nutrition, in neonates receiving neo-bulging diseaseor mixtures that are exclusively breastfed
Bleeding in gastric and duodenal ulcers Radiation disease Thrombocytopenic purpura Persistent hemorrhoidal( from the enlarged rectum veins) and nasal bleeding Bleeding in pulmonary tuberculosis, septic diseases Hemorrhagicsyndrome associated with hypoprothrombinemia, bleeding after wounds, injuries and surgical interventions. In the complex treatment of dysfunctional uterine bleeding, not associated with organic pathology, with menorrhagia. Violation of coagulation due to a decrease in the content of factors II, VII, IX, X, against the background of taking coumarin derivatives and indanedione, salicylates, some antibiotics. Hemorrhagic disease in newborns( prevention and treatment), incl.in newborns of high risk group - born from mothers who received anticoagulants.
How to use Vikasol-Darnitsa?
The drug is administered intramuscularly. Single dose - 10-15 mg, daily - 30 mg.
Children: newborns - up to 4 mg / day to 1 year - 2-5 mg / day, up to 2 years - 6 mg / day, 3-4 years - 8 mg / day, 5-9 years - 10 mg / day, 10-14 years - 15 mg / day.
Duration of treatment - 3-4 days, after a 4-day break, if necessary, repeat the course. When surgical interventions with possible severe parenchymal hemorrhage are prescribed within 2-3 days before the operation.
In cases of hemophilia and Verlhof disease, the drug is ineffective. Preventive prescription of vitamin K in the III trimester of pregnancy is ineffective due to its low permeability through the placenta.
The ability to influence the reaction rate when driving vehicles or other mechanisms.
During the treatment with the drug, it is possible to manage motor vehicles and engage in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.
Use during pregnancy or lactation.
Vikasol-Darnitsa refers to the drugs of risk in pregnancy. Its purpose is possible if the benefit to the mother exceeds the degree of risk to the fetus.
Side effects of Vikasola-Darnitsa.
- Allergic reactions: facial hyperemia, skin rash( including erythematous, urticaria), skin itching, bronchospasm.
- On the part of the blood system: hemolytic anemia, hemolysis in newborns with congenital deficiency of glucose-6-phosphate dehydrogenase.
- Local reactions: pain and swelling at the injection site, discoloration of the skin in the form of spots with repeated injections in the same place.
- From the cardiovascular system: transient reduction in blood pressure, tachycardia, "weak" filling of the pulse.
- Other: hyperbilirubinemia, jaundice( including nuclear jaundice in infants), dizziness, "profuse" sweat, change in taste sensations.
Who is contraindicated in Vikasol-Darnitsa?
Hypersensitivity to components of the drug. Hypercoagulation, thromboembolism. Hemolytic disease of newborns. Deficiency of glucose-6-phosphate dehydrogenase, severe hepatic insufficiency.
Interaction of Vikasola-Darnitsa.
Weaken the effect of indirect anticoagulants( including coumarin and indanedione derivatives).Does not affect the anticoagulant activity of heparin. Simultaneous administration with broad-spectrum antibiotics, quinidine, quinine, salicylates in high doses, sulfonamides requires an increase in the dose of vitamin K. When administered simultaneously with hemolytic drugs, the risk of side effects increases.
Symptoms: Vitamin K hypervitaminosis, which is manifested by hyperprothrombinemia and hyperthrombinemia, hyperbilirubinemia;in isolated cases, children develop toxicosis, manifested by convulsions.
Treatment. Cancel the drug. Under the control of indicators of the blood coagulation system, anticoagulants are prescribed.